| Cheryl Archbald, MD MPH | |
|
145 Huguenot St, Westchester Co. Dept Of Health, New Rochelle, NY 10801-5200 | |
| (914) 813-5227 | |
| (914) 813-5230 |
| Full Name | Cheryl Archbald |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 145 Huguenot St, New Rochelle, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538365333 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 206540 (New York) | Primary |
| Entity Name | Montefiore Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063525152 PECOS PAC ID: 3779496021 Enrollment ID: O20031113000235 |
News Archive
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
Completing 30 minutes of physical activity five days a week (150 mins a week) is associated with a reduced risk of death and cardiovascular disease, according to the largest study of physical activity tracking 130000 people in 17 countries published in The Lancet.
Poverty increases the risk of death and disability from non-communicable diseases, such as cancer, heart disease, stroke and diabetes in low- and middle-income countries, a new systematic review shows. Researchers also found evidence that developing an NCD increases the risk of falling into poverty in these countries.
Women who underwent a nonsurgical, image-guided treatment, uterine fibroid embolization (UFE), for the treatment of uterine fibroids experienced improved sexual function and a higher overall quality of life. The research, part of a French multicenter study, presented at the Society of Interventional Radiology's Annual Scientific Meeting, also found the vast majority of women treated with UFE sustained improvement for more than a year.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Cheryl Archbald, MD MPH 145 Huguenot St, Westchester Co. Dept. Of Health, New Rochelle, NY 10801-5200 Ph: (914) 813-5227 | Cheryl Archbald, MD MPH 145 Huguenot St, Westchester Co. Dept Of Health, New Rochelle, NY 10801-5200 Ph: (914) 813-5227 |
News Archive
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
Completing 30 minutes of physical activity five days a week (150 mins a week) is associated with a reduced risk of death and cardiovascular disease, according to the largest study of physical activity tracking 130000 people in 17 countries published in The Lancet.
Poverty increases the risk of death and disability from non-communicable diseases, such as cancer, heart disease, stroke and diabetes in low- and middle-income countries, a new systematic review shows. Researchers also found evidence that developing an NCD increases the risk of falling into poverty in these countries.
Women who underwent a nonsurgical, image-guided treatment, uterine fibroid embolization (UFE), for the treatment of uterine fibroids experienced improved sexual function and a higher overall quality of life. The research, part of a French multicenter study, presented at the Society of Interventional Radiology's Annual Scientific Meeting, also found the vast majority of women treated with UFE sustained improvement for more than a year.
› Verified 3 days ago
John M Leo, MD Pediatrics Medicare: Medicare Enrolled Practice Location: Sound Shore Pediatrics, 110 Lockwood Avenue, New Rochelle, NY 10801 Phone: 718-696-4060 | |
Dr. Margaret Levitt, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 16 Guion Pl, New Rochelle, NY 10801 Phone: 914-632-5000 | |
Maria Bartellino Damanakis, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 145 Huguenot St Ste 200, New Rochelle, NY 10801 Phone: 914-235-1400 | |
Dr. Mark Abramowicz, Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1000 Main St, New Rochelle, NY 10801 Phone: 914-235-0583 Fax: 914-576-3377 | |
William Joseph Meyers, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 140 Lockwood Ave, Suite 115, New Rochelle, NY 10801 Phone: 914-235-3800 Fax: 914-235-8185 | |
Dr. Aurora A Amurao, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 16 Guion Pl, New Rochelle, NY 10801 Phone: 914-632-5000 | |
Dr. Lisa Anne Marrero, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 16 Guion Pl, New Rochelle, NY 10801 Phone: 914-632-5000 |